Login Register Cart 0
Generic placeholder image

Adolescent Psychiatry

Editor-in-Chief

ISSN (Print): 2210-6766
ISSN (Online): 2210-6774

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Identifying Cannabidiol (CBD) Research Priorities Relevant to Child and Adolescent Psychiatry

Author(s): Leslie Hulvershorn*, Sally Weinstein, Kristina Bixler, Olivia K. Murray, Michael Smoker and Christopher Hammond

Volume 13, Issue 2, 2023

Published on: 01 September, 2023

Page: [63 - 79] Pages: 17

DOI: 10.2174/2210676613666230901143219

Price: $65

Abstract

Cannabidiol (CBD), a plant-derived cannabinoid compound found in cannabis, has been readily available in the United States since the legalization of hemp products in 2018. With all 50 states legalizing some form of CBD, many products have appeared in the marketplace. The American public generally considers CBD a safe and effective way to manage pain, mental health conditions, and other health issues in children and adults, even though CBD has only been approved for the treatment of specific types of pediatric seizures. This report describes early findings from preclinical CBD studies, select clinical trials, and naturalistic observational studies of CBD users and identifies knowledge gaps in this emerging field, especially those relating to the developmental effects of CBD. The main goal of this report is to identify priorities for future CBD research, particularly those that will benefit the field of child and adolescent psychiatry.

« Previous Next »
Agriculture Improvement Act of 2018 Available from: https://www.congress.gov/115/plaws/publ334/PLAW- 115publ334.pdf
Ahmed, K.T., Amin, M.R., Shah, P., Ali, D.W. (2018). Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (Δ9-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation. Sci. Rep., 8(1), 10518.

[http://dx.doi.org/10.1038/s41598-018-28689-z] [PMID: 30002406]
Americans' views on CBD products and marijuana for recreational use, (2019). Available from: https://www.politico.com/f/?id=0000016e-3d52-ddf0-ad6e-bfd38a2a0000
Anglesey, A. (2021). Customers got high after cannabis firm mixed up CBD and THC say regulators. Available from: https://www.newsweek.com/customers-got-high-after-cannabis-firm-mixed-cbd-thc-say-regulators-1632794(Accessed: September 26, 2021)
Atsmon, J., Cherniakov, I., Izgelov, D., Hoffman, A., Domb, A.J., Deutsch, L., Deutsch, F., Heffetz, D., Sacks, H. (2018). PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers. J. Pharm. Sci., 107(5), 1423-1429.

[http://dx.doi.org/10.1016/j.xphs.2017.12.020] [PMID: 29287930]
Ayano, G. (2016). Psychotropic medications metabolized by cytochromes P450 (CYP1A2) enzyme and relevant drug interactions: Review of articles. Austin J. Pharmacol. Ther., 4(2), 2-5.
Bachhuber, M.A., Arnsten, J.H., Starrels, J.L., Cunningham, C.O. (2018). Willingness to participate in longitudinal research among people with chronic pain who take medical cannabis: A cross-sectional survey. Cannabis Cannabinoid Res., 3(1), 45-53.

[http://dx.doi.org/10.1089/can.2017.0051] [PMID: 29607410]
Bartelink, I.H., Rademaker, C.M.A., Schobben, A.F.A.M., van den Anker, J.N. (2006). Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet., 45(11), 1077-1097.

[http://dx.doi.org/10.2165/00003088-200645110-00003] [PMID: 17048973]
Berger, M., Li, E., Rice, S., Davey, C.G., Ratheesh, A., Adams, S., Jackson, H., Hetrick, S., Parker, A., Spelman, T., Kevin, R., McGregor, I.S., McGorry, P., Amminger, G.P. (2022). Cannabidiol for treatmentresistant anxiety disorders in young people. J. Clin. Psychiatry, , 83(5), 21m14130.

[http://dx.doi.org/10.4088/JCP.21m14130] [PMID: 35921510]
Blessing, E.M., Steenkamp, M.M., Manzanares, J., Marmar, C.R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.

[http://dx.doi.org/10.1007/s13311-015-0387-1] [PMID: 26341731]
Bonn-Miller, M.O., Loflin, M.J.E., Thomas, B.F., Marcu, J.P., Hyke, T., Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708-1709.

[http://dx.doi.org/10.1001/jama.2017.11909] [PMID: 29114823]
Bouso, J.C., Jiménez-Garrido, D., Ona, G. , Woźnica, D., Santos, R.G., Hallak, J.E.C., Paranhos, B.A.P.B., Almeida Mendes, F., Yonamine, M., AlcázarCórcoles, M.Á., Farré, M.(2020).Quality of life, mental health, personality and patterns of use in self medicated cannabis users with chronic diseases: A 12 month longitudinal study. Phytother. Res., 34(7), 1670-1677.

[http://dx.doi.org/10.1002/ptr.6639] [PMID: 32083789]
Brasch, S. (2017). The cannavan helps marijuana researchers drive around some roadblocks. Available from: https://www.cpr.org/2017/11/02/the-cannavan-helps-marijuana-researchers-drive-around-some-roadblocks/
Britch, S.C., Babalonis, S., Walsh, S.L. (2021). Cannabidiol: Pharmacology and therapeutic targets. Psychopharmacology, 238(1), 9-28.

[http://dx.doi.org/10.1007/s00213-020-05712-8] [PMID: 33221931]
Brown, J., Winterstein, A. (2019). Potential adverse drug events and drug–drug interactions with medical and Consumer Cannabidiol (CBD) use. J. Clin. Med., 8(7), 989.

[http://dx.doi.org/10.3390/jcm8070989] [PMID: 31288397]
Brown, M. (2018). CBD oil for pregnancy: How moms are using it Available from: https://www.parents.com/pregnancy/everything-pregnancy/cbd-oil-for-preg- nancy-how-moms-are-using-it/
Carty, D.R., Miller, Z.S., Thornton, C., Pandelides, Z., Kutchma, M.L., Willett, K.L. (2019). Multigenerational consequences of early-life cannabinoid exposure in zebrafish. Toxicol. Appl. Pharmacol., 364, 133-143.

[http://dx.doi.org/10.1016/j.taap.2018.12.021] [PMID: 30594692]
Carty, D.R., Thornton, C., Gledhill, J.H., Willett, K.L. (2018). Developmental effects of cannabidiol and Δ9-tetrahydrocannabinol in zebrafish. Toxicol. Sci., 162(1), 137-145.

[http://dx.doi.org/10.1093/toxsci/kfx232] [PMID: 29106691]
Carvalho, R.K., Andersen, M.L., Mazaro-Costa, R. (2020). The effects of cannabidiol on male reproductive system: A literature review. J. Appl. Toxicol., 40(1), 132-150.

[http://dx.doi.org/10.1002/jat.3831] [PMID: 31313338]
Chen, A. (2017). Some of the parts: Is marijuana’s “entourage effect” scientifically valid. Sci. Am.
Cherniakov, I., Izgelov, D., Domb, A.J., Hoffman, A. (2017). The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur. J. Pharm. Sci., 109, 21-30.

[http://dx.doi.org/10.1016/j.ejps.2017.07.003] [PMID: 28736128]
Consroe, P., Kennedy, K., Schram, K. (1991). Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol. Biochem. Behav., 40(3), 517-522.

[http://dx.doi.org/10.1016/0091-3057(91)90357-8] [PMID: 1666917]
Dalterio, S., Steger, R., Mayfield, D., Bartke, A. (1984). Early cannabinoid exposure influences neuroendocrine and reproductive functions in male mice: I. Prenatal exposure. Pharmacol. Biochem. Behav., 20(1), 107-113. a

[http://dx.doi.org/10.1016/0091-3057(84)90110-2] [PMID: 6320227]
Dalterio, S., Steger, R., Mayfield, D., Bartke, A. (1984). Early cannabinoid exposure influences neuroendocrine and reproductive functions in mice: II. Postnatal effects. Pharmacol. Biochem. Behav., 20(1), 115-123. [b

[http://dx.doi.org/10.1016/0091-3057(84)90111-4] [PMID: 6320228]
Dalterio, S.L., deRooij, D.G. (1986). Maternal cannabinoid exposure Effects on spermatogenesis in male offspring. Int. J. Androl., 9(4), 250-258.

[http://dx.doi.org/10.1111/j.1365-2605.1986.tb00888.x] [PMID: 3026968]
Devinsky, O., Cross, J.H., Wright, S. (2017). Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N. Engl. J. Med., 377(7), 699-700.

[http://dx.doi.org/10.1056/NEJMc1708349] [PMID: 28813226]
Devinsky, O., Patel, A.D., Cross, J.H., Villanueva, V., Wirrell, E.C., Privitera, M., Greenwood, S.M., Roberts, C., Checketts, D., VanLandingham, K.E., Zuberi, S.M. (2018). Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N. Engl. J. Med., 378(20), 1888-1897. a

[http://dx.doi.org/10.1056/NEJMoa1714631] [PMID: 29768152]
Devinsky, O., Patel, A.D., Thiele, E.A., Wong, M.H., Appleton, R., Harden, C.L., Greenwood, S., Morrison, G., Sommerville, K. (2018). Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology, 90(14), e1204-e1211. b

[http://dx.doi.org/10.1212/WNL.0000000000005254] [PMID: 29540584]
Dharmapuri, S., Miller, K., Klein, J.D. (2020). Marijuana and the pediatric population. Pediatrics, 146(2), e20192629.

[http://dx.doi.org/10.1542/peds.2019-2629] [PMID: 32661188]
Elsaid, S., Kloiber, S., Le Foll, B. (2019). Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Prog. Mol. Biol. Transl. Sci., 167, 25-75.

[http://dx.doi.org/10.1016/bs.pmbts.2019.06.005] [PMID: 31601406]
Evans, D.G. (2020). Medical fraud, mislabeling, contamination: All common in CBD products. Mo. Med., 117(5), 394-399.
[PMID: 33311737]
Fasinu, P.S., Phillips, S., ElSohly, M.A., Walker, L.A. (2016). Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy, 36(7), 781-796.

[http://dx.doi.org/10.1002/phar.1780] [PMID: 27285147]
Fattore, L., Fratta, W. (2010). How important are sex differences in cannabinoid action? Br. J. Pharmacol., 160(3), 544-548.

[http://dx.doi.org/10.1111/j.1476-5381.2010.00776.x] [PMID: 20590564]
Ferber, S.G., Namdar, D., Hen-Shoval, D., Eger, G., Koltai, H., Shoval, G., Shbiro, L., Weller, A. (2020). The “entourage effect”: Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr. Neuropharmacol., 18(2), 87-96.

[http://dx.doi.org/10.2174/1570159X17666190903103923] [PMID: 31481004]
Fernandez, E., Perez, R., Hernandez, A., Tejada, P., Arteta, M., Ramos, J. (2011). Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics, 3(1), 53-72.

[http://dx.doi.org/10.3390/pharmaceutics3010053] [PMID: 24310425]
Finlay, D.B., Sircombe, K.J., Nimick, M., Jones, C., Glass, M. (2020). Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Front. Pharmacol., 11, 359.

[http://dx.doi.org/10.3389/fphar.2020.00359] [PMID: 32269529]
Garberg, H.T., Solberg, R., Barlinn, J., Martinez-Orgado, J., Løberg, E.M., Saugstad, O.D. (2017). High-dose cannabidiol induced hypotension after global hypoxia-ischemia in piglets. Neonatology, 112(2), 143-149.

[http://dx.doi.org/10.1159/000471786] [PMID: 28564654]
Gaston, T.E., Bebin, E.M., Cutter, G.R., Liu, Y., Szaflarski, J.P., Program, U.C. (2017). Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia, 58(9), 1586-1592.

[http://dx.doi.org/10.1111/epi.13852] [PMID: 28782097]
Goldstein, H., Harclerode, J., Nyquist, S.E. (1977). Effects of chronic administration of delta-9-tetrahydrocannabinol and cannabidiol on rat testicular esterase isozymes. Life Sci., 20(6), 951-954.

[http://dx.doi.org/10.1016/0024-3205(77)90280-6] [PMID: 850463]
Golombek, P., Müller, M., Barthlott, I., Sproll, C., Lachenmeier, D.W. (2020). Conversion of Cannabidiol (CBD) into psychotropic cannabinoids including Tetrahydrocannabinol (THC): A controversy in the scientific literature. Toxics, 8(2), 41.

[http://dx.doi.org/10.3390/toxics8020041] [PMID: 32503116]
Gunasekaran, N., Long, L.E., Dawson, B.L., Hansen, G.H., Richardson, D.P., Li, K.M., Arnold, J.C., McGregor, I.S. (2009). Reintoxication: The release of fat-stored Δ9-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. Br. J. Pharmacol., 158(5), 1330-1337.

[http://dx.doi.org/10.1111/j.1476-5381.2009.00399.x] [PMID: 19681888]
Gupta, M., Gupta, N., Fradkin, Y., Petti, T. (2023). Sleep Disturbances in Children and Adolescents with Autism Spectrum Disorder: An Overview for Clinicians. Adolesc. Psychiatry .

[http://dx.doi.org/10.2174/2210676613666230126115646]
Gupta, S. (2014). Medical marijuana and 'the entourage effect'. Available from: https://www.cnn.com/2014/03/11/health/gupta-marijuana-entourage/index.html
Gustafsson, S.B., Jacobsson, S.O.P. (2019). Effects of cannabinoids on the development of chick embryos in ovo. Sci. Rep., 9(1), 13486.

[http://dx.doi.org/10.1038/s41598-019-50004-7] [PMID: 31530885]
Guy, G.W., Robson, P.J. (2004). A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J. Cannabis Ther., 3(4), 121-152.

[http://dx.doi.org/10.1300/J175v03n04_02]
Congress.gov, Library of Congress (2018). Available from: https://www.congress.gov/
Hammell, D.C., Zhang, L.P., Ma, F., Abshire, S.M., McIlwrath, S.L., Stinchcomb, A.L., Westlund, K.N. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur. J. Pain, 20(6), 936-948.

[http://dx.doi.org/10.1002/ejp.818] [PMID: 26517407]
Hammond, C.J., Chaney, A., Hendrickson, B., Sharma, P. (2020). Cannabis use among U.S. adolescents in the era of marijuana legalization: A review of changing use patterns, comorbidity, and health correlates. Int. Rev. Psychiatry, 32(3), 221-234.

[http://dx.doi.org/10.1080/09540261.2020.1713056] [PMID: 32026735]
Hammond, C.J., Moon, Y.J., Fristad, M., Kady, A., Schneck, C.D., Sullivan, A.E. (2021). Impact of marijuana legislation on marijuana and cannabidiol related attitudes, perceptions, and behaviors among adolescents receiving mood disorder treatment in the United States. Available from: https://nndc.org/wp-content/uploads/2021/09/Clinical-Programs-Hammond-Zoom.pdf
Hilborn, H. (2019). 2018 Farm Bill Legalizes Hemp, but obstacles to sale of CBD products remain Available from:https://www.natlawreview.com/article/2018-farm-bill-legalizes-hemp-obstacles-to-sale-cbd-products-remain
Hindley, G., Beck, K., Borgan, F., Ginestet, C.E., McCutcheon, R., Kleinloog, D., Ganesh, S., Radhakrishnan, R., D’Souza, D.C., Howes, O.D. (2020). Psychiatric symptoms caused by cannabis constituents: A systematic review and meta-analysis. Lancet Psychiatry, 7(4), 344-353.

[http://dx.doi.org/10.1016/S2215-0366(20)30074-2] [PMID: 32197092]
Hložek, T., Uttl, L. (2017). ., Kadeřábek, L., Balíková, M., Lhotková, E., Horsley, R.R., Nováková, P., Šíchová, K., Štefková, K., Tylš, F., Kuchař, M., Páleníček, T. (2017) Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur. Neuropsychopharmacol., 27(12), 1223-1237.

[http://dx.doi.org/10.1016/j.euroneuro.2017.10.037] [PMID: 29129557]
Hurd, Y.L., Manzoni, O.J., Pletnikov, M.V., Lee, F.S., Bhattacharyya, S., Melis, M. (2019). Cannabis and the Developing Brain: Insights into its long-lasting effects. J. Neurosci., 39(42), 8250-8258. a

[http://dx.doi.org/ 10.1523/JNEUROSCI.1165-19.2019] [PMID: 31619494]
Hurd, Y.L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A.M., Salsitz, E. (2019). Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: . . A double-blind randomized placebo-controlled trial. Am. J. Psychiatry, 176(11), 911-922. b

[http://dx.doi.org/10.1176/appi.ajp.2019.18101191] [PMID: 31109198]
Ibeas Bih, C., Chen, T., Nunn, A.V.W., Bazelot, M., Dallas, M., Whalley, B.J. (2015). Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 12(4), 699-730.

[http://dx.doi.org/10.1007/s13311-015-0377-3] [PMID: 26264914]
Jones, C.A., Watson, D.J.G., Fone, K.C.F. (2011). Animal models of schizophrenia. Br. J. Pharmacol., 164(4), 1162-1194.

[http://dx.doi.org/10.1111/j.1476-5381.2011.01386.x] [PMID: 21449915]
Jones, N. (2020). Should you give your kid CBD?. Available from: https://www.nytimes.com/2020/04/30/parenting/cbd-oil-children.html
Karcher, N.R., Barch, D.M. (2020). The ABCD study: Understanding the development of risk for mental and physical health outcomes. Neuropsychopharmacology.

[http://dx.doi.org/10.1038/s41386-020-0736-6] [PMID: 32541809]
Leas, E.C., Hendrickson, E.M., Nobles, A.L., Todd, R., Smith, D.M., Dredze, M., Ayers, J.W. (2020). Self-reported Cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw. Open, 3(10), e2020977.

[http://dx.doi.org/10.1001/jamanetworkopen.2020.20977] [PMID: 33057645]
Lewis, M. (2021). Is CBD an option for Autism Spectrum Disorder?. Available from: https://www.remedyreview.com/data/autism-and-cbd/
Long, L.E., Chesworth, R., Huang, X.F., Wong, A., Spiro, A., McGregor, I.S., Arnold, J.C., Karl, T. (2012). Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One, 7(4), e34129.

[http://dx.doi.org/10.1371/journal.pone.0034129] [PMID: 22509273]
Lucas, C.J., Galettis, P., Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol., 84(11), 2477-2482.

[http://dx.doi.org/10.1111/bcp.13710] [PMID: 30001569]
Manini, A.F., Yiannoulos, G., Bergamaschi, M.M., Hernandez, S., Olmedo, R., Barnes, A.J., Winkel, G., Sinha, R., Jutras-Aswad, D., Huestis, M.A., Hurd, Y.L. (2015). Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J. Addict. Med., 9(3), 204-210.

[http://dx.doi.org/10.1097/ADM.0000000000000118] [PMID: 25748562]
Martinelli, K. (2021). CBD: What Parents Need to Know. Available from: https://childmind.org/article/cbd-what-parents-need-to-know/#full_article
Medicine, U. S. N. L. (2019). Cannabidiol as a medication for neuropsychiatric and other medical conditions - An in vivo innovative drug delivery study NCT03471559.
Melas, P.A., Scherma, M., Fratta, W., Cifani, C., Fadda, P. (2021). Cannabidiol as a potential treatment for anxiety and mood disorders: Molecular targets and epigenetic insights from preclinical research. Int. J. Mol. Sci., 22(4), 1863.

[http://dx.doi.org/10.3390/ijms22041863] [PMID: 33668469]
Metternich, B., Wagner, K., Geiger, M. J., Hirsch, M., Schulze-Bonhage, A., Klotz, K. A. (2021). Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. . Epilepsy Behav.,, 114(Pt A ), 107558.

[http://dx.doi.org/ 10.1016/j.yebeh.2020.107558]
Millar, S.A., Stone, N.L., Yates, A.S., O’Sullivan, S.E. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Front. Pharmacol., 9, 1365.

[http://dx.doi.org/10.3389/fphar.2018.01365] [PMID: 30534073]
Miller, M.L., Chadwick, B., Dickstein, D.L., Purushothaman, I., Egervari, G., Rahman, T., Tessereau, C., Hof, P.R., Roussos, P., Shen, L., Baxter, M.G., Hurd, Y.L. (2019). Adolescent exposure to Δ9-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons. Mol. Psychiatry, 24(4), 588-600.

[http://dx.doi.org/10.1038/s41380-018-0243-x] [PMID: 30283037]
Miller, O.S., Elder, E.J., Jr, Jones, K.J., Gidal, B.E. (2022). Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Epilepsy Behav., 127, 108514.

[http://dx.doi.org/10.1016/j.yebeh.2021.108514] [PMID: 34998268]
Mlost, J., Bryk, M., Starowicz, K. (2020). Cannabidiol for pain treatment: Focus on pharmacology and mechanism of action. Int. J. Mol. Sci., 21(22), 8870.

[http://dx.doi.org/10.3390/ijms21228870] [PMID: 33238607]
Moltke, J., Hindocha, C. (2021). Reasons for cannabidiol use: A cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J. Cannabis Res., 3(1), 5.

[http://dx.doi.org/10.1186/s42238-021-00061-5] [PMID: 33602344]
Murray, R.M., Englund, A., Abi-Dargham, A., Lewis, D.A., Di Forti, M., Davies, C., Sherif, M., McGuire, P., D’Souza, D.C. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89-104.

[http://dx.doi.org/10.1016/j.neuropharm.2017.06.018] [PMID: 28634109]
National Conference of State Legislatures (2021) State industrial hemp statutes. Available from: https://www.ncsl.org/research/agriculture-and-rural-development/state-industrial-hemp-statutes.aspx
National Institute of Mental Health. (2021). Adolescent Brain Cognitive Development Study (ABCD) - Annual release 4.0. Available from: https://nda.nih.gov/study.html?id=1299
Ohlsson, A., Lindgren, J.E., Andersson, S., Agurell, S., Gillespie, H., Hollister, L.E. (1986). Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biol. Mass Spectrom., 13(2), 77-83.

[http://dx.doi.org/10.1002/bms.1200130206] [PMID: 2937482]
Owermohle, S. (2019). Why we don’t know much about pot. Available from: https://www.politico.com/agenda/story/2019/10/14/cannabis-medical-marijuana-research-000984/
Pavlovic, R., Nenna, G., Calvi, L., Panseri, S., Borgonovo, G., Giupponi, L., Cannazza, G., Giorgi, A. (2018). Quality traits of “Cannabidiol Oils”: Cannabinoids content, terpene fingerprint and oxidation stability of european commercially available preparations. Molecules, 23(5), 1230.

[http://dx.doi.org/10.3390/molecules23051230] [PMID: 29783790]
Peres, F.F., Diana, M.C., Levin, R., Suiama, M.A., Almeida, V., Vendramini, A.M., Santos, C.M., Zuardi, A.W., Hallak, J.E.C., Crippa, J.A., Abílio, V.C. (2018). Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia. Front. Pharmacol., 9, 901.

[http://dx.doi.org/10.3389/fphar.2018.00901] [PMID: 30186164]
Sarrafpour, S., Urits, I., Powell, J., Nguyen, D., Callan, J., Orhurhu, V., Simopoulos, T., Viswanath, O., Kaye, A.D., Kaye, R.J., Cornett, E.M., Yazdi, C. (2020). Considerations and implications of cannabidiol use during pregnancy. Curr. Pain Headache Rep., 24(7), 38.

[http://dx.doi.org/10.1007/s11916-020-00872-w] [PMID: 32524214]
Sellers, E.M., Schoedel, K., Bartlett, C., Romach, M., Russo, E.B., Stott, C.G., Wright, S., White, L., Duncombe, P., Chen, C.F. (2013). A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT/QTc study to evaluate the electrophysiologic effects of THC/CBD spray. Clin. Pharmacol. Drug Dev., 2(3), 285-294.

[http://dx.doi.org/10.1002/cpdd.36] [PMID: 27121791]
Sharma, P., Holland, A., Sheikh, T., Oesterle, T., Platt, R., Hammond, C.J. (2022). Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study. PEC Innov., 1, 100044.
Singer, L., Tokish, H., Park, F., Campisi, C., Milanaik, R.L. (2020). The cannabidiol conundrum: Potential benefits and risks of cannabidiol products for children. Curr. Opin. Pediatr., 32(1), 198-205.

[http://dx.doi.org/10.1097/MOP.0000000000000861] [PMID: 31833952]
Solowij, N., Broyd, S., Greenwood, L., van Hell, H., Martelozzo, D., Rueb, K., Todd, J., Liu, Z., Galettis, P., Martin, J., Murray, R., Jones, A., Michie, P.T., Croft, R. (2019). A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: Acute intoxication effects. Eur. Arch. Psychiatry Clin. Neurosci., 269(1), 17-35.

[http://dx.doi.org/10.1007/s00406-019-00978-2] [PMID: 30661105]
Stott, C., White, L., Wright, S., Wilbraham, D., Guy, G. (2013). A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus, 2(1), 236.

[http://dx.doi.org/10.1186/2193-1801-2-236] [PMID: 23750331]
Stott, C.G., White, L., Wright, S., Wilbraham, D., Guy, G.W. (2013). A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur. J. Clin. Pharmacol., 69(5), 1135-1147.

[http://dx.doi.org/10.1007/s00228-012-1441-0] [PMID: 23179176]
Stout, S.M., Cimino, N.M. (2014). Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metab. Rev., 46(1), 86-95.

[http://dx.doi.org/10.3109/03602532.2013.849268] [PMID: 24160757]
Substance Abuse and Mental Health Services Administration (2021). 2020 NSDUH detailed tables. Available from: https://www.samhsa.gov/data/report/2020-nsduh-detailed-tables
Sun, A., Sullivan, A., Leffler, J.M., Hammond, C.J., Miller, L. Review of the efficacy and safety of cannabidiol with a focus on children and adolescents in the treatment of psychiatric symptoms and disorders. Adolesc. Psychiatry.
Taking Research to the Streets (2022). The Cannabis Scientist. Available from: https://thecannabisscientist.com/research-development/taking-researchto-the-streets
Taylor, L., Gidal, B., Blakey, G., Tayo, B., Morrison, G. (2018). A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs, 32(11), 1053-1067.

[http://dx.doi.org/10.1007/s40263-018-0578-5] [PMID: 30374683]
Thiele, E.A., Marsh, E.D., French, J.A., Mazurkiewicz-Beldzinska, M., Benbadis, S.R., Joshi, C., Lyons, P.D., Taylor, A., Roberts, C., Sommerville, K., Gunning, B., Gawlowicz, J., Lisewski, P., Mazurkiewicz Beldzinska, M., Mitosek Szewczyk, K., Steinborn, B., Zolnowska, M., Hughes, E., McLellan, A., Benbadis, S., Ciliberto, M., Clark, G., Dlugos, D., Filloux, F., Flamini, R., French, J., Frost, M., Haut, S., Joshi, C., Kapoor, S., Kessler, S., Laux, L., Lyons, P., Marsh, E., Moore, D., Morse, R., Nagaraddi, V., Rosenfeld, W., Seltzer, L., Shellhaas, R., Sullivan, J., Thiele, E., Thio, L.L., Wang, D., Wilfong, A. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 391(10125), 1085-1096.

[http://dx.doi.org/10.1016/S0140-6736(18)30136-3] [PMID: 29395273]
U.S. National Library of Medicine (2021). A double-blind, randomized, placebo-controlled clinical trial of adjunctive cannabidiol for bipolar depression. NCT03310593.
U.S. National Library of Medicine. (2021). A randomized controlled test of the effects of CHI-907 on experiences of test anxiety among college students. NCT04269252.
University of New South Wales National Drug & Alcohol Research Centre. (2014). Cannabidiol (CBD) for the management of cannabis withdrwawal: A phase II proof of concept open label study Available from: https://ndarc.med.unsw.edu.au/project/cannabidiol-cbd-management-cannabis-withdrawal-phase-ii-proof-concept-open-label-study
University of Sydney A randomised controlled trial of cannabidiol for the treatment of alcohol withdrawal. Available from: https://www.sydney.edu.au/research/volunteer-for-research-study/psychology-and-mental-health/a-randomised-controlled-trial-of-cannabidiol--cbd--for-the-treat.html
Vandrey, R. (2019). Interactions between cannabinoids and cytochrome P450-metabolized drugs. NCT04201197.
Vandrey, R., Raber, J.C., Raber, M.E., Douglass, B., Miller, C., Bonn-Miller, M.O. (2015). Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA, 313(24), 2491-2493.

[http://dx.doi.org/10.1001/jama.2015.6613] [PMID: 26103034]
Woodcock, J. (2023). FDA Concludes the existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol, will work with Congress on a new way forward Available from: https://www.fda.gov/news-events/press-announcements/fda-concludes-existingregulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol
Worth, T. (2019). Cannabis’s chemical synergies. Nature, 572(7771), S12-S13.

[http://dx.doi.org/10.1038/d41586-019-02528-1] [PMID: 31462791]
Zgair, A., Wong, J.C., Lee, J.B., Mistry, J., Sivak, O., Wasan, K.M., Hennig, I.M., Barrett, D.A., Constantinescu, C.S., Fischer, P.M., Gershkovich, P. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am. J. Transl. Res., 8(8), 3448-3459.
[PMID: 27648135]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy